Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Celator PharmaceuticalsJun 7 2011

Celator Pharmaceuticals today announced positive clinical results in elderly patients with newly-diagnosed secondary acute myeloid leukemia (sAML) treated with CPX-351 (cytarabine:daunorubicin) Liposome Injection. Data were presented as a poster discussion at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois. The results were based on a subgroup analysis, after 12 months of follow-up, in a randomized Phase 2b trial that compared CPX-351 to conventional cytarabine and daunorubicin (7+3 regimen), the current standard of care (ASCO Abstract #6519).

"Our observation that high-risk patients, particularly those with secondary AML, had greater improvements with CPX-351 led us to take this detailed look at the secondary AML population in this study," said Jeffrey E. Lancet, M.D., associate professor, H. Lee Moffitt Cancer Center, and the study's principal investigator. "The results suggested CPX-351 produced a higher number of remissions, lower early mortality, and more importantly a significant improvement in overall survival compared to 7+3 therapy. We believe these findings provide good rationale for a Phase 3 study of CPX-351 in patients with previously untreated secondary AML."

The randomized, open-label Phase 2b study enrolled patients between the ages of 60-75 years with newly-diagnosed AML at 18 sites in the United States and Canada. Patients were stratified as high risk (age ≥70, sAML, or ≥3 chromosomal abnormalities) or standard risk (all other patients). A total of 51 patients were enrolled with a diagnosis of sAML, including prior blood disorders (antecedent hematological disorders), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), chronic myelomonocytic leukemia (CMMoL), or treatment-related AML. Following randomization, 32 of these patients received CPX-351 and 19 received 7+3.

CPX-351 produced a higher rate of aplasia (81.3% vs 57.9%) and resulted in a nearly 25% absolute improvement in remission rate (56.3% vs 31.6%) compared to the 7+3 arm. Furthermore, patients with sAML treated with CPX-351 had lower early mortality (Day 60: 6.3% vs 31.6%) and an improvement in event-free survival (median 3.8 months vs 1.4 months). 

Treatment with CPX-351 was associated with well-characterized and manageable adverse events. The myelosuppressive effect of CPX-351 was greater than 7+3, with slower neutrophil and platelet recovery (~11-12 days longer), effects consistent with the pharmacokinetics of CPX-351. This prolonged myelosuppression was associated with increased infection and bleeding events but no increase in early mortality. Non-myelosuppressive adverse events were qualitatively similar between the two groups, with higher rates of nausea, rash, cough, and headache in the CPX-351 arm.

"We are very excited by the benefits seen with CPX-351 in patients with AML," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "The promising survival benefit of CPX-351 seen in secondary AML patients compared to the 7+3 regimen, in this difficult to treat population, is quite compelling. Additionally, the Company met with FDA in May and is scheduled to meet with the European Medicines Agency in June. We believe this regulatory input and randomized Phase 2 data enables us to design and initiate a Phase 3 pivotal trial and brings us closer to providing a safe and effective therapy for patients with secondary AML."